Batra Mansi, Gupta Sumeet, Nair Anroop B, Dhanawat Meenakshi, Sandal Suraj, Morsy Mohamed Aly
Department of Clinical Practice, M. M. College of Pharmacy, M. M. (Deemed to be University), Mullana (Ambala), Haryana, India.
Department of Pharmacology, M. M. College of Pharmacy, M. M. (Deemed to be University), Mullana (Ambala), Haryana, India.
Eur J Ophthalmol. 2021 Sep;31(5):2237-2244. doi: 10.1177/11206721211008783. Epub 2021 Apr 10.
Vision impairment remains a major health problem worldwide. Elevated intraocular pressure is a prime risk factor for blindness in the elderly. Netarsudil is a Rho-associated protein kinase (ROCK) inhibitor, which also inhibits norepinephrine transport. This narrative review summarizes the properties and clinical significance of netarsudil, a promising drug in topical glaucoma therapy.
We searched PubMed, Medline and Scopus databases using relevant keywords to retrieve information on the physicochemical properties, formulation, mechanism of action, clinical pharmacokinetics, dose and toxicity of netarsudil.
Netarsudil showed promising effects in lowering the elevated intraocular pressure by two mechanisms. The US FDA approved netarsudil for clinical use in 2017 under the trademark of Rhopressa while European Medicines Agency approved Rhokiinsa in 2019. This drug is available as a 0.02% ophthalmic solution for once-daily topical application.
The discovery of netarsudil is a breakthrough in the therapy of glaucoma with proven efficacy in a wide range of eye pressures and is well tolerated in cases with ocular hypertension and chronic glaucoma.
视力损害仍是全球主要的健康问题。眼压升高是老年人失明的主要危险因素。奈他地尔是一种Rho相关蛋白激酶（ROCK）抑制剂，它也抑制去甲肾上腺素转运。本叙述性综述总结了奈他地尔的特性及临床意义，奈他地尔是一种在局部青光眼治疗中有前景的药物。
我们使用相关关键词搜索了PubMed、Medline和Scopus数据库，以检索有关奈他地尔的理化性质、剂型、作用机制、临床药代动力学、剂量和毒性的信息。
奈他地尔通过两种机制在降低升高的眼压方面显示出有前景的效果。美国食品药品监督管理局（US FDA）于2017年批准奈他地尔以Rhopressa为商标用于临床，而欧洲药品管理局于2019年批准了Rhokiinsa。该药物有0.02%的眼药水剂型，每日一次局部使用。
奈他地尔的发现是青光眼治疗的一项突破，在广泛的眼压范围内已证实其疗效，并且在高眼压症和慢性青光眼患者中耐受性良好。
